We are live on ! Find out more
NKGN

NKGen Biotech, Inc. Common Stock
NKGN

Delisted

NKGN was delisted on the 4th of March, 2025.

Back to rankings

1 hedge funds and large institutions have $165K invested in NKGen Biotech, Inc. Common Stock in 2026 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 1 → 1 (0)

14% less capital invested

Capital invested by funds: $193K → $165K (-$27.6K)

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter

NKGN Hedge Fund Activity: Q2 2026 in Review

1 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Common Stock (NKGN) for Q2 2026, worth a combined $165K — down 14% from $193K a quarter earlier.

Fund positioning in NKGN was balanced in Q2 2026: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 1 institutional investor held NKGen Biotech, Inc. Common Stock (NKGN) as of Q2 2026, unchanged from Q1 2026.
  • Funds reported $165K of NKGen Biotech, Inc. Common Stock stock for Q2 2026, down 14% quarter-over-quarter.
  • 0 funds opened new NKGen Biotech, Inc. Common Stock positions in Q2 2026 and 0 closed out.

Based on aggregated 13F filings for Q2 2026.